

**27. MAY**

SESSION A | 12:00 - 14:00 CET

We would like to invite you to our webcast, the 10 Years of Simplicity, Join us for this 2-hour, interactive webcast to discuss Trajenta® and how 10 years of experience have helped simplify the management of type 2 diabetes for physicians and patients worldwide. Hear perspectives from leading international experts in the treatment of type 2 diabetes. See the detailed agenda below.



🕒 12:00 - 12:05

**Welcome to 10 Years of Trajenta®**

- Webcast objectives and introduction of Chair

🎤 Professor Per Henrik Groop and Dr Sarah Jarvis

🕒 12:05 - 12:35

**10 Years of Improvement in T2D Patient Care**

- Chair to introduce faculty
- Paradigm shift in T2D guidelines based on evidence of proven CV benefit
- The role of DPP4i in treatment of T2D and the evolution of the Trajenta® profile (proven efficacy,<sup>1</sup> convenience, followed by CV and kidney safety from CVOTs)

🎤 Professor Clifford J. Bailey

🕒 12:35 - 12:55

**CARMELINA® and CAROLINA®: An Extensive Dataset From A Unique CVOT Programme**

- Robust CV and kidney safety data from CARMELINA® and CAROLINA® in patients across a broad spectrum of T2D disease duration, CV and kidney risk
- Trajenta® is the only DPP4i with 2 large CVOTs, including an active-comparator trial

🎤 Professor Nikolaus Marx

🕒 12:55 - 13:15

**Can A Broad Range of T2D Patients Benefit From The Simplicity of Linagliptin?**

- Proven efficacy<sup>1</sup> for a broad range of patients, and convenience of always one dose, once daily
- Data from CARMELINA® and CAROLINA® subgroup analyses support CV and kidney safety profile of Trajenta® and continue to generate scientific evidence from the CVOT programme

🎤 Professor Per-Henrik Groop

🕒 13:15 - 13:35

**Defining Simplicity in Clinical Practice – A Case-Driven Approach**

- Patient cases incorporating speaker experience with Trajenta®
- Data from Trajenta® CVOTs support treatment decision making

🎤 Dr Sarah Jarvis

🕒 13:35 - 13:45

**Summarising The Advances That Linagliptin Has Brought to T2D Care**

- Vast experience with Trajenta®
- Highlights of Trajenta® simplicity (efficacy, safety, convenience)

🎤 Professor Per-Henrik Groop

🕒 13:45 - 14:00

**Q&A and Close**

- Audience Q&A
- Moderator to reinforce the simplicity of Trajenta® and close the webcast

🎤 Professor Per-Henrik Groop and Dr Sarah Jarvis

1. Trajenta® EMA Summary of Product Characteristics. October 2019.